MIS416 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02228213 (ClinicalTrials.gov)	October 2014	21/8/2014	Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis	A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Biological: MIS416;Drug: Saline	Innate Immunotherapeutics	INC Research	Completed	18 Years	70 Years	All	93	Phase 2	Australia;New Zealand
2	NCT01191996 (ClinicalTrials.gov)	August 2010	30/8/2010	Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis	A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Biological: MIS416	Innate Immunotherapeutics	Primorus Clinical Trials;National Multiple Sclerosis Society	Completed	18 Years	N/A	Both	34	Phase 1/Phase 2	New Zealand